The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function

John P. Mulhall, Spencer Land, Marilyn Parker, W. Bedford Waters, Robert C. Flanigan, Arthur L. Burnett, Ralph W deVere White

Research output: Contribution to journalArticle

176 Citations (Scopus)

Abstract

Purpose. It has been suggested that postradical prostatectomy (RP) erectile function outcomes are improved by early use of erectogenic medications. This analysis was designed to assess the ability of a post-RP vasoactive drug program to improve long-term spontaneous erectile function. Methods. Men with functional preoperative erections who underwent RP were challenged early postoperatively with oral sildenafil. Nonresponders were switched to intracavernosal injection therapy (ICI). Patients were instructed to inject three times a week. Only patients who presented within 6 months post RP, who completed the International Index of Erectile Function (IIEF) questionnaire on at least three separate occasions after surgery, and who had been followed for at least 18 months were included. Data from men who were committed to rehabilitation were compared with those of men who did not follow the protocol but continued to be followed serially following RP. Results. There were 58 patients in the rehabilitation (R) group and 74 in the nonrehabilitation (NR) group. No differences existed in mean patient age, comorbidity profile, intraoperative nerve sparing status, or postoperative erectile hemodynamics between the two groups. At 18 months post RP, there were statistically significant differences between the two groups in the percentage of patients who were capable of having medication-unassisted intercourse (R = 52% vs. NR = 19%, P < 0.001); mean erectile rigidity (R = 53 ± 21% vs. NR = 26 ± 43%, P < 0.01); mean IIEF erectile function (EF) domain scores (R = 22 ± 6 vs. NR = 12 ± 14, P < 0.01); the percentage of patients with normal EF domain scores (R = 22% vs. NR = 6%, P < 0.01); the percentage of patients responding to sildenafil (R = 64% vs. NR = 24%, P < 0.001); the time to become a sildenafil responder (R = 9 ± 4 vs. NR = 13 ± 3 months, P = 0.02); and the percentage of patients responding to ICI (R = 95% vs. NR = 76%, P < 0.01). Conclusions. The data generated from this nonrandomized study indicate that a pharmacologic penile rehabilitation protocol results in higher rates of spontaneous functional erections and erectogenic drug response after RP.

Original languageEnglish (US)
Pages (from-to)532-542
Number of pages11
JournalJournal of Sexual Medicine
Volume2
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Prostatectomy
Rehabilitation
Injections
Pharmaceutical Preparations
Comorbidity
Hemodynamics
Therapeutics
Sildenafil Citrate

Keywords

  • Iatrogenic sexual dysfunction
  • Intraurethral and intracavernosal theraphy
  • Oral vasoactive agents

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology

Cite this

The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function. / Mulhall, John P.; Land, Spencer; Parker, Marilyn; Waters, W. Bedford; Flanigan, Robert C.; Burnett, Arthur L.; deVere White, Ralph W.

In: Journal of Sexual Medicine, Vol. 2, No. 4, 2005, p. 532-542.

Research output: Contribution to journalArticle

Mulhall, John P. ; Land, Spencer ; Parker, Marilyn ; Waters, W. Bedford ; Flanigan, Robert C. ; Burnett, Arthur L. ; deVere White, Ralph W. / The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function. In: Journal of Sexual Medicine. 2005 ; Vol. 2, No. 4. pp. 532-542.
@article{62f240ba458d46019cbbda4230781718,
title = "The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function",
abstract = "Purpose. It has been suggested that postradical prostatectomy (RP) erectile function outcomes are improved by early use of erectogenic medications. This analysis was designed to assess the ability of a post-RP vasoactive drug program to improve long-term spontaneous erectile function. Methods. Men with functional preoperative erections who underwent RP were challenged early postoperatively with oral sildenafil. Nonresponders were switched to intracavernosal injection therapy (ICI). Patients were instructed to inject three times a week. Only patients who presented within 6 months post RP, who completed the International Index of Erectile Function (IIEF) questionnaire on at least three separate occasions after surgery, and who had been followed for at least 18 months were included. Data from men who were committed to rehabilitation were compared with those of men who did not follow the protocol but continued to be followed serially following RP. Results. There were 58 patients in the rehabilitation (R) group and 74 in the nonrehabilitation (NR) group. No differences existed in mean patient age, comorbidity profile, intraoperative nerve sparing status, or postoperative erectile hemodynamics between the two groups. At 18 months post RP, there were statistically significant differences between the two groups in the percentage of patients who were capable of having medication-unassisted intercourse (R = 52{\%} vs. NR = 19{\%}, P < 0.001); mean erectile rigidity (R = 53 ± 21{\%} vs. NR = 26 ± 43{\%}, P < 0.01); mean IIEF erectile function (EF) domain scores (R = 22 ± 6 vs. NR = 12 ± 14, P < 0.01); the percentage of patients with normal EF domain scores (R = 22{\%} vs. NR = 6{\%}, P < 0.01); the percentage of patients responding to sildenafil (R = 64{\%} vs. NR = 24{\%}, P < 0.001); the time to become a sildenafil responder (R = 9 ± 4 vs. NR = 13 ± 3 months, P = 0.02); and the percentage of patients responding to ICI (R = 95{\%} vs. NR = 76{\%}, P < 0.01). Conclusions. The data generated from this nonrandomized study indicate that a pharmacologic penile rehabilitation protocol results in higher rates of spontaneous functional erections and erectogenic drug response after RP.",
keywords = "Iatrogenic sexual dysfunction, Intraurethral and intracavernosal theraphy, Oral vasoactive agents",
author = "Mulhall, {John P.} and Spencer Land and Marilyn Parker and Waters, {W. Bedford} and Flanigan, {Robert C.} and Burnett, {Arthur L.} and {deVere White}, {Ralph W}",
year = "2005",
doi = "10.1111/j.1743-6109.2005.00081_1.x",
language = "English (US)",
volume = "2",
pages = "532--542",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function

AU - Mulhall, John P.

AU - Land, Spencer

AU - Parker, Marilyn

AU - Waters, W. Bedford

AU - Flanigan, Robert C.

AU - Burnett, Arthur L.

AU - deVere White, Ralph W

PY - 2005

Y1 - 2005

N2 - Purpose. It has been suggested that postradical prostatectomy (RP) erectile function outcomes are improved by early use of erectogenic medications. This analysis was designed to assess the ability of a post-RP vasoactive drug program to improve long-term spontaneous erectile function. Methods. Men with functional preoperative erections who underwent RP were challenged early postoperatively with oral sildenafil. Nonresponders were switched to intracavernosal injection therapy (ICI). Patients were instructed to inject three times a week. Only patients who presented within 6 months post RP, who completed the International Index of Erectile Function (IIEF) questionnaire on at least three separate occasions after surgery, and who had been followed for at least 18 months were included. Data from men who were committed to rehabilitation were compared with those of men who did not follow the protocol but continued to be followed serially following RP. Results. There were 58 patients in the rehabilitation (R) group and 74 in the nonrehabilitation (NR) group. No differences existed in mean patient age, comorbidity profile, intraoperative nerve sparing status, or postoperative erectile hemodynamics between the two groups. At 18 months post RP, there were statistically significant differences between the two groups in the percentage of patients who were capable of having medication-unassisted intercourse (R = 52% vs. NR = 19%, P < 0.001); mean erectile rigidity (R = 53 ± 21% vs. NR = 26 ± 43%, P < 0.01); mean IIEF erectile function (EF) domain scores (R = 22 ± 6 vs. NR = 12 ± 14, P < 0.01); the percentage of patients with normal EF domain scores (R = 22% vs. NR = 6%, P < 0.01); the percentage of patients responding to sildenafil (R = 64% vs. NR = 24%, P < 0.001); the time to become a sildenafil responder (R = 9 ± 4 vs. NR = 13 ± 3 months, P = 0.02); and the percentage of patients responding to ICI (R = 95% vs. NR = 76%, P < 0.01). Conclusions. The data generated from this nonrandomized study indicate that a pharmacologic penile rehabilitation protocol results in higher rates of spontaneous functional erections and erectogenic drug response after RP.

AB - Purpose. It has been suggested that postradical prostatectomy (RP) erectile function outcomes are improved by early use of erectogenic medications. This analysis was designed to assess the ability of a post-RP vasoactive drug program to improve long-term spontaneous erectile function. Methods. Men with functional preoperative erections who underwent RP were challenged early postoperatively with oral sildenafil. Nonresponders were switched to intracavernosal injection therapy (ICI). Patients were instructed to inject three times a week. Only patients who presented within 6 months post RP, who completed the International Index of Erectile Function (IIEF) questionnaire on at least three separate occasions after surgery, and who had been followed for at least 18 months were included. Data from men who were committed to rehabilitation were compared with those of men who did not follow the protocol but continued to be followed serially following RP. Results. There were 58 patients in the rehabilitation (R) group and 74 in the nonrehabilitation (NR) group. No differences existed in mean patient age, comorbidity profile, intraoperative nerve sparing status, or postoperative erectile hemodynamics between the two groups. At 18 months post RP, there were statistically significant differences between the two groups in the percentage of patients who were capable of having medication-unassisted intercourse (R = 52% vs. NR = 19%, P < 0.001); mean erectile rigidity (R = 53 ± 21% vs. NR = 26 ± 43%, P < 0.01); mean IIEF erectile function (EF) domain scores (R = 22 ± 6 vs. NR = 12 ± 14, P < 0.01); the percentage of patients with normal EF domain scores (R = 22% vs. NR = 6%, P < 0.01); the percentage of patients responding to sildenafil (R = 64% vs. NR = 24%, P < 0.001); the time to become a sildenafil responder (R = 9 ± 4 vs. NR = 13 ± 3 months, P = 0.02); and the percentage of patients responding to ICI (R = 95% vs. NR = 76%, P < 0.01). Conclusions. The data generated from this nonrandomized study indicate that a pharmacologic penile rehabilitation protocol results in higher rates of spontaneous functional erections and erectogenic drug response after RP.

KW - Iatrogenic sexual dysfunction

KW - Intraurethral and intracavernosal theraphy

KW - Oral vasoactive agents

UR - http://www.scopus.com/inward/record.url?scp=22144465483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144465483&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2005.00081_1.x

DO - 10.1111/j.1743-6109.2005.00081_1.x

M3 - Article

VL - 2

SP - 532

EP - 542

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 4

ER -